Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Summary

Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.

Timeline

Start

2026-04-01

Primary completion

2028-12-31

Completion

2029-01-30

Drugs

Indications